Trial Profile
Phase I Trial of TAS-102 and Concurrent Radiation Therapy for Patients With Locally Recurrent, Unresectable or Metastatic, Rectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions
- 18 Feb 2022 Status changed from active, no longer recruiting to completed.
- 22 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 16 Mar 2020 Status changed from recruiting to active, no longer recruiting.